CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that it will hold an analyst and investor day on October 13, 2016 in New York City, where the company will share updates on its progress in research and development, with a focus on hematopoietic stem cell programs. The event and live webcast will begin at 9:00 a.m. ET. To access the live webcast, please visit the “Events & Presentations” page within the Investors and Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcasts will be available on the bluebird bio website for 90 days following the event.
